Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions

被引：0
|
作者：
Grazia Dell’Agnello
Alessandro Zuddas
Gabriele Masi
Paolo Curatolo
Dante Besana
Andrea Rossi
机构：
[1] Eli Lilly Italia S.p.A,Medical Department
[2] University of Cagliari,Child Neurology and Psychiatry, Department of Neuroscience
[3] IRCCS Stella Maris,Pediatric Neuroscience Unit
[4] Scientific Institute of Child Neurology and Psychiatry,undefined
[5] Torvergata University,undefined
[6] Operating Structure of Infantile Neuropsychiatry Infantile Hospital,undefined
[7] Hospital Agency of Alessandria,undefined
来源：
CNS Drugs | 2009年 / 23卷
关键词：
Autism Spectrum Disorder; Oppositional Defiant Disorder; ADHD Symptom; Atomoxetine; Pervasive Developmental Disorder;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Attention-deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioural disorders in children. It has been shown that as many as 85% of patients with ADHD have at least one psychiatric comorbidity, and approximately 60% have at least two.
引用
收藏
页码：739 / 753
页数：14
相关论文
共 50 条
  • [1] Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions
    Dell'Agnello, Grazia
    Zuddas, Alessandro
    Masi, Gabriele
    Curatolo, Paolo
    Besana, Dante
    Rossi, Andrea
    [J]. CNS DRUGS, 2009, 23 (09) : 739 - 753
  • [2] Atomoxetine as an Adjunct Therapy in the Treatment of Co-Morbid Attention-Deficit/Hyperactivity Disorder in Children and Adolescents with Bipolar I or II Disorder
    Chang, Kiki
    Nayar, Daphne
    Howe, Meghan
    Rana, Manasi
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2009, 19 (05) : 547 - 551
  • [3] THE EFFICACY OF ATOMOXETINE AS ADJUNCTIVE TREATMENT FOR CO-MORBID ATTENTION DEFICIT HYPERACTIVITY AND SUBSTANCE USE DISORDERS
    Viswanath, B.
    Narayanaswamy, J. C.
    Jose, S. P.
    Chakraborthy, V.
    Muralidharan, K.
    Benegal, V.
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2010, 34 (06) : 179A - 179A
  • [4] THE EFFICACY OF ATOMOXETINE AS ADJUNCTIVE TREATMENT FOR CO-MORBID ATTENTION DEFICIT HYPERACTIVITY DISORDER AND ALCOHOLISM AND OTHER SUBSTANCE USE DISORDERS
    Benegal, V.
    Viswanath, B.
    Muralidharan, K.
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2010, 34 (08) : 154A - 154A
  • [5] Atomoxetine for the treatment of attention-deficit/hyperactivity disorder
    Davids, E
    Gastpar, M
    [J]. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2004, 72 (10) : 586 - 591
  • [6] Atomoxetine treatment of attention-deficit/hyperactivity disorder
    Eiland, LS
    Guest, AL
    [J]. ANNALS OF PHARMACOTHERAPY, 2004, 38 (01) : 86 - 90
  • [7] Screening for attention-deficit hyperactivity disorder and co-morbid mental disorders among prison inmates
    Einarsson, Emil
    Sigurdsson, Jon Fridrik
    Gudjonsson, Gisli H.
    Newton, Anna Kristin
    Bragason, Olafur Orn
    [J]. NORDIC JOURNAL OF PSYCHIATRY, 2009, 63 (05) : 361 - 367
  • [8] Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction
    Perez de los Cobos, Jose
    Sinol, Nuria
    Perez, Victor
    Trujols, Joan
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (02) : 337 - 356
  • [9] Prevalence of attention-deficit/hyperactivity disorder and co-morbid disorders among students of Cumhuriyet University
    Kavakci, Onder
    Kugu, Nesim
    Semiz, Murat
    Meydan, Feride
    Karsikaya, Sureyya
    Dogan, Orhan
    [J]. EUROPEAN JOURNAL OF PSYCHIATRY, 2012, 26 (02): : 107 - 117
  • [10] A Diagnostic Dilemma: Co-Morbid Attention Deficit Hyperactivity Disorder and Bipolar Disorder in Geriatric Patients
    Heard, Erika N.
    Poscablo-Stein, Cristina
    Sohail, Yousef
    Nagar, Anusuiya
    Hermida, Adriana P.
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2017, 25 (03): : S65 - S65
12345